ArticleBlood advances2022
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation.
Abstract read
In one paragraph
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial.Journal of hematology & oncology · 2024Trial
- Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events.Blood · 2023Trial
- Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model.Journal for immunotherapy of cancer · 2026Article
- Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.Transplantation and cellular therapy · 2025Review
- Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part IV. Patient Important Outcomes.Transplantation and cellular therapy · 2025Article
- Article
- Human OX40L-CAR-TScience translational medicine · 2024Article
- The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals.Blood advances · 2024Article
- Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation.Blood advances · 2024Article
- The Evolution of Hematopoietic Stem Cell Transplantation to Overcome Access Disparities: The Role of NMDP.Cells · 2024Article
- Factors Associated with Opting Out of an Unrelated Hematopoietic Stem Cell Donor Registry: Differences and Similarities across Five Key Groups of Young Race/Ethnically Diverse Potential Donors in the United States.Transplantation and cellular therapy · 2024Article
- Novel approaches to acute graft-versus-host disease prevention.Hematology. American Society of Hematology. Education Program · 2023Review
- Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis.Bone marrow transplantation · 2023Article
- Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT.Bone marrow transplantation · 2023Article
- Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.Transplantation and cellular therapy · 2023Observational
- Role of abatacept in the prevention of graft-Therapeutic advances in hematology · 2023Review
- Celebrating a year of clinical and translational research in Blood Advances.Blood advances · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Muna QayedAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, GA.
Benjamin WatkinsAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, GA.
Scott GillespieDepartment of Pediatrics, Emory University, Atlanta, GA.
Brandi BratrudeBoston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-1498-1001
Kayla BetzBoston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA.
Sung W ChoiDepartment of Pediatrics, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-6321-3834
Jeffrey DavisBC Children's Hospital, University of British Columbia, Vancouver, Canada.
Christine DuncanBoston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA.
Roger GillerCenter for Cancer and Blood Disorders, Children Hospital of Colorado, University of Colorado, Aurora, CO.
Michael GrimleyUniversity of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0003-2056-5167
Andrew C HarrisUniversity of Utah, Primary Children's Hospital, Salt Lake City, UT.ORCID 0000-0002-4538-8817
David JacobsohnChildren's National Health System, Washington, DC.
Nahal LalefarUniversity of California San Francisco, UCSF Benioff Children's Hospital Oakland, Oakland, CA.
Maxim NorkinBaptist Medical Center Jacksonville, Jacksonville, FL.
Nosha FarhadfarUniversity of Florida, UF Health Shands Hospital, Gainesville, FL.
Michael A PulsipherChildren's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, CA.ORCID 0000-0003-3030-8420
Shalini ShenoyWashington University School of Medicine, St. Louis, MO.
Aleksandra PetrovicSeattle Children's Hospital, Seattle, WA; and.
Kirk R SchultzBC Children's Hospital, University of British Columbia, Vancouver, Canada.
Gregory A YanikDepartment of Pediatrics, University of Michigan, Ann Arbor, MI.
Edmund K WallerWinship Cancer Institute, Emory University, Atlanta, GA.ORCID 0000-0003-0816-6729
Amelia LangstonWinship Cancer Institute, Emory University, Atlanta, GA.ORCID 0000-0003-0649-1915
Leslie S KeanBoston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA.
John T HoranBoston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA.
Funding
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3MPhase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHDR01FD004099 · FDA · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2013 to 2016
$1.7MUnrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant ConsortiumUG1HL069254 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S · 2017 to 2023
$1.3MFDA HHS R01 FD004099NHLBI NIH HHS R01 HL095791NHLBI NIH HHS UG1 HL069254
Abstract
PubMed holds no abstract for this paper.
Indexed as
Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAbataceptHumansTransplantation ConditioningUnrelated DonorsAbatacept
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.